HIV Capsid Inhibitor Solid Forms for Stability and Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiretroviral therapies for HIV-1 infections face challenges with the emergence of resistant strains, necessitating the development of new antiretroviral agents and improved pharmaceutical formulations.
Innovation Solution
The development of solid forms, including pharmaceutically acceptable salts and cocrystals of the HIV capsid inhibitor Compound 1, which can be crystallized in various forms to enhance stability, bioavailability, and manufacturability, along with methods to enrich specific isomeric forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antiretroviral therapies are used to treat HIV-1 infections, then viral load is reduced and disease progression is delayed, but resistant strains emerge
Solution Approach 1:
The patent applies parameter changes by developing new chemical compounds with modified molecular structures and properties. The invention synthesizes and characterizes new compounds with specific physical and chemical parameters (purity, stability, bioavailability) that differ from existing antiretroviral agents, thereby creating therapies that can overcome viral resistance while maintaining effectiveness.
Solution Approach 2:
The patent employs composite materials by creating pharmaceutical compositions that combine multiple compounds or compounds with different functional properties. The invention develops formulations that integrate new synthetic compounds with appropriate excipients and delivery systems, creating composite pharmaceutical products that enhance therapeutic efficacy and reduce the emergence of resistant strains.
2Reliability
If new antiretroviral agents are developed to overcome resistance, then treatment effectiveness is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies parameter changes by optimizing manufacturing parameters such as purification methods, crystallization conditions, and formulation parameters. The invention systematically varies these parameters to achieve the desired compound properties while maintaining manufacturability, thereby reducing the complexity of producing new antiretroviral agents.
Solution Approach 2:
The patent employs copying by utilizing established pharmaceutical manufacturing processes and techniques that can be replicated and scaled. The invention adapts proven synthesis methods and formulation approaches to create new compounds, thereby reducing the learning curve and manufacturing complexity associated with developing novel antiretroviral therapies.
3Quantity of substance
If pharmaceutical formulations are improved for better bioavailability, then drug efficacy is enhanced, but formulation complexity increases
Solution Approach 1:
The patent applies parameter changes by modifying formulation parameters such as particle size, crystal structure, excipient composition, and delivery route. The invention systematically optimizes these parameters to enhance bioavailability and drug efficacy while maintaining formulation simplicity, thereby achieving better absorption without excessive complexity.
Solution Approach 2:
The patent employs segmentation by dividing the formulation into distinct functional components with specific roles. The invention separates the active compound from excipients and delivery systems, allowing each component to be optimized independently while maintaining overall formulation simplicity, thereby enhancing bioavailability without increasing overall complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solid forms of the HIV capsid inhibitor provide improved stability, bioavailability, and manufacturability, addressing the need for effective treatment of HIV infections and potentially overcoming resistance issues.
Implementation Method 1
The present disclosure relates to solid forms of an HIV capsid inhibitor, including pharmaceutically acceptable salts and cocrystals of the inhibitor, as well as crystalline forms of the salts and cocrystals
Implementation Method 2
contacting the starting mixture with an acid or a base in the presence of a solvent to form a salt mixture of both isomeric compounds
Data Source
AI summary
The present disclosure relates to pharmaceutically acceptable salts, cocrystals, and crystalline forms thereof, of a compound which is N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2- ((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-TH-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.